Cartesian Therapeutics, Inc. Comprehensive Income
Cartesian Therapeutics, Inc. (RNAC) reported Comprehensive Income of $15.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- Cartesian Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $15.74M, a 0.97% decline year-over-year.
- Cartesian Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$39.19M.
- Cartesian Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$92.56M.
- Cartesian Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$35.91M.
- Cartesian Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$130.26M.
- Cartesian Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$77.44M.
- Cartesian Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$219.75M, a 721.00% decline from fiscal 2022.
- Cartesian Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $35.39M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.74M 10-Q · filed 2026-08-06 | -$23.45M 10-Q · filed 2026-08-06 | -$116.01M derived: sum of 3 quarters · filed 2026-08-06 | -$151.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$39.19M 10-Q · filed 2026-04-30 | -$131.75M derived: sum of 2 quarters · filed 2026-04-30 | -$167.67M derived: sum of 3 quarters · filed 2026-04-30 | -$151.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$92.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$128.48M derived: sum of 2 quarters · filed 2026-03-09 | -$112.58M derived: sum of 3 quarters · filed 2026-08-06 | -$130.26M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$35.91M 10-Q · filed 2025-11-06 | -$20.01M derived: sum of 2 quarters · filed 2026-08-06 | -$37.69M 10-Q · filed 2025-11-06 | -$47.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $15.90M 10-Q · filed 2026-08-06 | -$1.78M 10-Q · filed 2026-08-06 | -$12.05M derived: sum of 3 quarters · filed 2026-08-06 | -$36.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$17.68M 10-Q · filed 2026-04-30 | -$27.95M derived: sum of 2 quarters · filed 2026-04-30 | -$52.14M derived: sum of 3 quarters · filed 2026-04-30 | -$38.29M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$10.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$34.47M derived: sum of 2 quarters · filed 2026-03-09 | -$20.62M derived: sum of 3 quarters · filed 2026-03-09 | -$77.44M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$24.20M 10-Q · filed 2025-11-06 | -$10.35M derived: sum of 2 quarters · filed 2025-11-06 | -$67.18M 10-Q · filed 2025-11-06 | -$244.82M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $13.85M 10-Q · filed 2025-08-07 | -$42.98M 10-Q · filed 2025-08-07 | -$220.62M derived: sum of 3 quarters · filed 2025-08-07 | -$229.64M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$56.83M 10-Q · filed 2025-05-08 | -$234.47M derived: sum of 2 quarters · filed 2025-05-08 | -$243.49M derived: sum of 3 quarters · filed 2025-05-08 | -$254.91M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$177.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$186.66M derived: sum of 2 quarters · filed 2025-03-13 | -$198.08M derived: sum of 3 quarters · filed 2025-03-13 | -$219.75M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$9.02M 10-Q · filed 2024-11-07 | -$20.44M derived: sum of 2 quarters · filed 2024-11-07 | -$42.11M 10-Q · filed 2024-11-07 | -$36.24M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$11.41M 10-Q · filed 2024-08-08 | -$33.09M 10-Q · filed 2024-08-08 | -$27.22M derived: sum of 3 quarters · filed 2024-08-08 | -$35.17M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$21.67M 10-Q · filed 2024-05-08 | -$15.81M derived: sum of 2 quarters · filed 2024-05-08 | -$23.75M derived: sum of 3 quarters · filed 2024-05-08 | -$15.03M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$2.08M derived: sum of 2 quarters · filed 2024-03-07 | $6.64M derived: sum of 3 quarters · filed 2024-03-07 | $35.39M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$7.94M 10-Q · filed 2023-11-13 | $776.00K derived: sum of 2 quarters · filed 2023-11-13 | $29.52M 10-Q · filed 2023-11-13 | $41.75M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $8.72M 10-Q · filed 2023-08-17 | $37.47M 10-Q · filed 2023-08-17 | $49.70M derived: sum of 3 quarters · filed 2024-03-07 | $31.80M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $28.75M 10-Q · filed 2023-05-04 | $40.98M derived: sum of 2 quarters · filed 2024-03-07 | $23.08M derived: sum of 3 quarters · filed 2024-03-07 | $27.66M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $12.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$5.66M derived: sum of 2 quarters · filed 2024-03-07 | -$1.09M derived: sum of 3 quarters · filed 2024-03-07 | -$25.69M 10-K · filed 2024-03-07 |
| 2021-09-30 | -$17.90M 10-Q · filed 2022-11-03 | -$13.32M derived: sum of 2 quarters · filed 2022-11-03 | -$37.92M 10-Q · filed 2022-11-03 | -$53.35M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $4.58M 10-Q · filed 2022-08-08 | -$20.03M 10-Q · filed 2022-08-08 | -$35.45M derived: sum of 3 quarters · filed 2023-03-02 | -$45.21M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | -$24.60M 10-Q · filed 2022-05-05 | -$40.03M derived: sum of 2 quarters · filed 2023-03-02 | -$49.79M derived: sum of 3 quarters · filed 2023-03-02 | -$73.84M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | -$15.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$25.19M derived: sum of 2 quarters · filed 2023-03-02 | -$49.24M derived: sum of 3 quarters · filed 2023-03-02 | -$68.92M 10-K · filed 2023-03-02 |
| 2020-09-30 | -$9.76M 10-Q · filed 2021-11-09 | -$33.81M derived: sum of 2 quarters · filed 2021-11-09 | -$53.49M 10-Q · filed 2021-11-09 | -$68.37M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | -$24.05M 10-Q · filed 2021-08-12 | -$43.73M 10-Q · filed 2021-08-12 | -$58.61M derived: sum of 3 quarters · filed 2022-03-10 | -$70.61M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | -$19.68M 10-Q · filed 2021-05-13 | -$34.56M derived: sum of 2 quarters · filed 2022-03-10 | -$46.56M derived: sum of 3 quarters · filed 2022-03-10 | -$62.95M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | -$14.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$26.88M derived: sum of 2 quarters · filed 2022-03-10 | -$43.27M derived: sum of 3 quarters · filed 2022-03-10 | -$55.32M 10-K · filed 2022-03-10 |
| 2019-09-30 | -$12.00M 10-Q · filed 2020-11-05 | -$28.39M derived: sum of 2 quarters · filed 2020-11-05 | -$40.44M 10-Q · filed 2020-11-05 | -$55.13M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | -$16.39M 10-Q · filed 2020-08-06 | -$28.44M 10-Q · filed 2020-08-06 | -$43.13M derived: sum of 3 quarters · filed 2021-03-12 | -$59.17M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | -$12.05M 10-Q · filed 2020-05-07 | -$26.74M derived: sum of 2 quarters · filed 2021-03-12 | -$42.78M derived: sum of 3 quarters · filed 2021-03-12 | -$61.66M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | -$14.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$30.73M derived: sum of 2 quarters · filed 2021-03-12 | -$49.61M derived: sum of 3 quarters · filed 2021-03-12 | -$65.47M 10-K · filed 2021-03-12 |
| 2018-09-30 | -$16.04M 10-Q · filed 2019-11-08 | -$34.92M derived: sum of 2 quarters · filed 2019-11-08 | -$50.78M 10-Q · filed 2019-11-08 | -$70.34M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$18.87M 10-Q · filed 2019-08-08 | -$34.74M 10-Q · filed 2019-08-08 | -$54.30M derived: sum of 3 quarters · filed 2020-03-12 | -$68.97M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$15.87M 10-Q · filed 2019-05-09 | -$35.42M derived: sum of 2 quarters · filed 2020-03-12 | -$50.09M derived: sum of 3 quarters · filed 2020-03-12 | -$66.09M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$19.55M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$34.23M derived: sum of 2 quarters · filed 2020-03-12 | -$50.23M derived: sum of 3 quarters · filed 2020-03-12 | -$65.22M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$14.67M 10-Q · filed 2018-11-08 | -$30.67M derived: sum of 2 quarters · filed 2018-11-08 | -$45.67M 10-Q · filed 2018-11-08 | -$59.72M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | -$16.00M 10-Q · filed 2018-08-08 | -$31.00M 10-Q · filed 2018-08-08 | -$45.04M derived: sum of 3 quarters · filed 2019-03-15 | -$52.74M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | -$15.00M 10-Q · filed 2018-05-09 | -$29.04M derived: sum of 2 quarters · filed 2019-03-15 | -$36.74M derived: sum of 3 quarters · filed 2019-03-15 | -$43.49M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | -$14.05M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | -$21.74M derived: sum of 2 quarters · filed 2019-03-15 | -$28.50M derived: sum of 3 quarters · filed 2019-03-15 | -$35.74M 10-K · filed 2019-03-15 |
| 2016-09-30 | -$7.70M 10-Q · filed 2017-11-07 | -$14.45M derived: sum of 2 quarters · filed 2017-11-07 | -$21.70M 10-Q · filed 2017-11-07 | -$28.89M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | -$6.75M 10-Q · filed 2017-08-11 | -$14.00M 10-Q · filed 2017-08-11 | -$21.19M derived: sum of 3 quarters · filed 2018-03-15 | -$27.72M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-03-31 | -$7.25M 10-Q · filed 2017-05-11 | -$14.44M derived: sum of 2 quarters · filed 2018-03-15 | -$20.97M derived: sum of 3 quarters · filed 2018-03-15 | -$27.59M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-12-31 | -$7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$13.72M derived: sum of 2 quarters · filed 2018-03-15 | -$20.34M derived: sum of 3 quarters · filed 2018-03-15 | -$26.28M 10-K · filed 2018-03-15 |
| 2015-09-30 | -$6.53M 10-Q · filed 2016-11-10 | -$13.15M derived: sum of 2 quarters · filed 2016-11-10 | -$19.09M 10-Q · filed 2016-11-10 | |
| 2015-06-30 | -$6.62M 10-Q · filed 2016-08-09 | -$12.56M 10-Q · filed 2016-08-09 | ||
| 2014-12-31 | -$16.16M 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |